Cargando…
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report
Pembrolizumab, an immune checkpoint inhibitor against the programmed death-1 pathway, has been used in combination with acitinib for the first-line treatment of advanced renal cell carcinoma. Neurotoxicity is a rare immune-related adverse event (irAE). The present study reports a case of Guillain-Ba...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265222/ https://www.ncbi.nlm.nih.gov/pubmed/32499912 http://dx.doi.org/10.3892/mco.2020.2042 |